Search Result for:
Medical Oncology
Browse:
Education by Topic
New Online Offerings
Certificate Programs
Translated Offerings
Annual Global Meeting
Sort By
This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease.
On-Demand
Kathleen Moore details outcome measures from three major phase III trials—KEYNOTE-B96, ROSELLA, and MIRASOL—highlighting objective response rates, progression-free and overall survival, and key safety signals.
On-Demand
Dr. Robert Coleman with moderation by Dr. Floor Backes and Dr. Wendel Naumman. Dr. Coleman explores the evolving treatment strategies for recurrent platinum-sensitive ovarian cancer, drawing on the latest clinical trial data and real-world outcomes.
On-Demand
This 2-hour webinar will bring together international experts to explore evolving molecular insights, treatment trends, and clinical challenges in uterine cancer through lectures and a tumor board discussion.
On-Demand
 This course offers an in-depth exploration of personalized treatment approaches for endometrial cancers, focusing on proficient mismatch repair (pMMR), deficient mismatch repair (dMMR) diseases and molecular classification in the recurrent setting.
On-Demand
Listen to a new Journal Club with PI Dr. Brian Slomovitz and moderator Dr. Leslie Randall as they discuss details on the New England Journal of Medicine published article Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
On-Demand
Listen to a new Journal Club with lead author Dr. Angeles Alvarez Secord and moderator Dr. Robert Coleman as they discuss details on the recently published article The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.
On-Demand
Results of Phase II PICCOLO Trial are available. Dr. Angeles Alvarez Secord, PI of PICCOLO Trial, and Dr. Wendel Naumann discuss results of MIRV in Recurrent Platinum-Sensitive Ovarian Cancer with High Folate Receptor-Alpha Expression.  
On-Demand
Treatment options for patients with advanced or recurrent endometrial cancers are rapidly evolving. Dr. Vicky Makker shares recent report from ASCO 2024 on Selinexor, a novel oral maintenance therapy for patients with TP53 wild type advanced or recurrent endometrial cancer. 
On-Demand
Led by Dr. Floor Backes and Dr. Wendel Naumann, the Advances & Updates workgroup of the IGCS Education Committee collaborates with our industry partners year-round to provide our global community with current and future therapeutics in gynecologic cancer.
On-Demand
New trial in progress enrollment information for advanced and recurrent endometrial cancer - Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042.
On-Demand
Listen to Dr. Matthew Powell and Dr. Wendel Naumann discuss the 2024 SGO Annual Meeting on Women’s Cancer late-breaking abstract Overall survival in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY.
On-Demand
The RAMP 301 trial is evaluating the novel combination of avutometinib + defactinib versus investigator’s choice of therapy in patients with recurrent low grade serous ovarian cancer.
On-Demand
This webinar included faculty discussing the practicalities of choosing available tumor and germline testing options along with treatment options. 
On-Demand
IGCS and Eisai welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the first presentation from the An Evolving Frontier - Understanding Novel Treatment Options for The Management of Advanced Stage or Recurrent Endometrial Cancers Industry Supported Symposium presented at the IGCS 2023 Annual Global Meeting in Seoul, South Korea.
On-Demand
Hear from Dr. Ramez Eskander as he teaches learners to understand the options to treat mismatch repair deficient endometrial cancer and we will discuss what to consider at the time of recurrence in the setting of prior immunotherapy. 
On-Demand
Listen to Dr. Rachel Grisham as she shares results from her IGCS 2023 late-breaking presentation from Seoul.
On-Demand
Listen to international experts as they discuss state of the art of maintenance in first and second line, criteria for choosing treatment, and unmet needs. 
On-Demand
Didactic presentation recorded in June 2023. 
On-Demand
Course 1 to 20 of 33